Catumaxomab--trifunctional anti-EpCAM antibody used to treat malignant ascites

Expert Opinion on Biological Therapy
Carsten Bokemeyer

Abstract

Malignant ascites is a sign of advanced tumour growth and is associated with significant morbidity and a poor prognosis with a median survival time of a few months. Paracentesis is a recommended treatment for malignant ascites, but can cause complications, for example infections, injury of abdominal organs, persistent leakage of ascites, and haematoma/haemorrhage. The European Medicines Agency (EMA) approved the use of a trifunctional bispecific antibody, catumaxomab (Removab), for the intraperitoneal (i.p.) treatment of malignant ascites in April 2009. This review describes the tailored preclinical and the clinical development of catumaxomab for the i.p. treatment of malignant ascites from 1998 to 2009. Relevant toxicology and pharmacokinetic findings are reported as well as main results of a large international Phase II/III study that was pivotal in the EMA approval of catumaxomab. Catumaxomab i.p. treatment results in a significant and clinically relevant improvement of puncture-free survival time and time to first need for puncture compared with paracentesis alone. The related side effects of catumaxomab treatment are predictable and related to the antibody's mode of action.

References

Jan 1, 1992·Cytopathology : Official Journal of the British Society for Clinical Cytology·M De AngelisW Gray
Apr 1, 1994·The Journal of Cell Biology·S V LitvinovS O Warnaar
Apr 7, 2000·The American Journal of Pathology·H HashizumeD M McDonald
Dec 20, 2000·Proceedings of the National Academy of Sciences of the United States of America·Y S ChangL L Munn
Jun 19, 2001·The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society·R RiesenbergH Lindhofer
Jan 28, 2004·Human Pathology·Philip Th WentStephan Dirnhofer
Feb 27, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Neil Kaplowitz
Sep 30, 2004·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·C BokemeyerP Soubeyran
Dec 17, 2004·Journal of Cellular and Molecular Medicine·Wen-Xing Ding, Xiao-Ming Yin
May 21, 2005·International Journal of Cancer. Journal International Du Cancer·Markus M HeissHorst Lindhofer
Oct 6, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Karine Passebosc-FaureChristian Genin
Jan 26, 2006·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Gerhild BeckerHubert E Blum
Nov 10, 2006·The New England Journal of Medicine·Todd W ThomsenGary S Setnik
Feb 13, 2007·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·A AyhanK Yuce
Feb 15, 2007·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A A Ayantunde, S L Parsons
Jul 4, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Alexander BurgesRainer Kimmig
Sep 4, 2007·Journal of Clinical Pharmacology·Kathleen Seitz, Honghui Zhou

❮ Previous
Next ❯

Citations

Sep 15, 2010·Carcinogenesis·Bernardina T F van der GunMarianne G Rots
Feb 5, 2013·Expert Opinion on Biological Therapy·Umberto Leone Roberti MaggioreSimone Ferrero
Feb 11, 2016·Journal of Controlled Release : Official Journal of the Controlled Release Society·Priyanka BhattRajashree Mashru
Dec 25, 2012·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Sarantos Kyriakopoulos, Cleo Kontoravdi
Sep 19, 2012·Journal of Molecular Biology·Fabrice Le GallSergej M Kiprijanov
Jan 10, 2012·International Journal of Pharmaceutics·John G ElvinChristopher F van der Walle
Sep 29, 2011·Critical Reviews in Oncology/hematology·Santiago Aparo, Sanjay Goel
Dec 22, 2014·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·C F JehnD Lüftner
Jul 23, 2013·Methods : a Companion to Methods in Enzymology·Brian D HarmsAlexey A Lugovskoy
Oct 15, 2018·Journal of Cellular Physiology·Vahideh TarhrizShirin Eyvazi
Apr 12, 2016·Nihon yakurigaku zasshi. Folia pharmacologica Japonica·Nobuaki TakahashiKazuma Tomizuka
Mar 20, 2019·Journal of Immunology Research·Shixue ChenLei Zhao
May 14, 2016·Oncology Reports·Shin Young ParkWoo Sung Moon
Jun 9, 2012·Drugs·James E Frampton
Jun 5, 2018·Annals of Gastroenterological Surgery·Joji KitayamaNaohiro Sata
Feb 13, 2019·Molecular Medicine Reports·Lucyna Kapka-SkrzypczakMarcin Kruszewski
Jun 13, 2018·Molecular Cancer Therapeutics·Wilhem LeconetNeil H Bander

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antibody Engineering

Antibody engineering technologies are constantly advancing to improve the clinical effectiveness of monoclonal and bispecific antibodies. Discover the latest research on Antibody Engineering here.